Biologics Working Party outlines information for quality portion of investigational applications
This article was originally published in The Gold Sheet
Executive Summary
A new guideline from the European Medicines Agency's Biologics Working Party notes that "there are clear differences between the requirements for a dossier for a clinical trial and a marketing authorization dossier. While the latter has to ensure a consistent, state-of-the-art quality of a product for widespread use in patients, information to be provided in an IMP should mainly focus on those quality attributes related to safety aspects." The deadline for public comment is Aug. 31
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.